Menu Back to Annual-Canadian-Meeting

Overview

October 16: Short Courses
October 17-18: Meeting

Preconference Short Course 1: Quality Stream
Preconference Short Course 2: ICH Clinical Safety and Efficacy


The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current bio-pharma and device landscape in Canada, while sharing insights into Canada’s broader role in global health care product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing to key regulatory and clinical considerations for biologics and biosimilars, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe.

As Canada celebrates its 150 years of Confederation in 2017, the DIA Annual Canadian Meeting will explore how Canada’s past has set the stage for future innovation in its health care ecosystem. Bringing together key stakeholders from the pharmaceutical and device industries, regulatory agencies, and academia, this Meeting will analyze the relevant challenges and opportunities for professionals working in drug and device development in Canada.

This year’s meeting will feature preconference short courses, plenary sessions, multi-track breakout sessions tailored to the beginner, intermediate, and advanced level professional, and multiple networking opportunities.
 
NEW! This year the DIA Annual Canadian Meeting will be co-located with DIA's Canadian Pharmacovigilance and Risk Management Conference. Maximize your education and time by attending both!



Highlights

  • Two ICH Short Courses — Learn the latest ICH updates from industry and regulatory experts
    • Designed to advance understanding of the ICH guidelines, with emphasis on Q12, Q9, Q10, E6, E17, E11, and E9
    • Case-based learning, presentations, and open discussion
  • Networking/Exhibitor reception
  • Three concurrent breakout sessions allowing you to customize your learning experience
  • Discounted entertainment and dining through our partners at the Ottawa Convention and Visitors Bureau
  • Co-located with our other premier DIA Canadian event: Canadian Pharmacovigilance and Risk Management Strategies Conference

Who should attend?

Professionals involved in:

  • Regulatory
  • Policy
  • Clinical trial disclosure policies and compliance
  • Clinical operations or clinical research
  • Medical writing and communications
  • Legal
  • Market access

Learning objectives

At the conclusion of this meeting, participants should be able to:

  • Describe the current and evolving regulatory environment in Canada and celebrate successes to make Canada 150
  • Learn about regulatory priorities and current topics of interest in the regulatory landscape
  • Summarize methods and approaches in various aspects of clinical trials, patient engagement, supply chain, and manufacturing
  • Discuss and learn more in-depth approaches on international harmonization, worksharing, and adoption of guidelines
  • Review and examine the various levels of transparency and postmarket activities that are underway

Program Committee

  • Marilena  Bassi, MA
    Marilena Bassi, MA Director, Therapeutic Products Directorate
    Health Canada, Canada
  • Deirdre  Cozier
    Deirdre Cozier Senior Manager, Regulatory Affairs
    Pendopharm, Division of Pharmascience, Canada
  • Loretta  Del Bosco
    Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
    AbbVie Corporation, Canada
  • Laura  Durno, MS, MSc
    Laura Durno, MS, MSc Acting Chief, Viral Vaccines Division
    Biologics and Genetic Therapies Directorate, Health Canada, Canada
  • Karen  Feltmate
    Karen Feltmate President
    Redstone Health Group, Inc., Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Director, Regulatory Affairs; Worldwide Safety and Regulatory-Innovative
    Pfizer Canada Inc, Canada
  • Maggie  Graham
    Maggie Graham Senior Policy Analyst, Natural and Non-Prescription Health Products Directorate
    Health Canada, Canada
  • Keith  McIntosh
    Keith McIntosh Executive Director, Scientific & Regulatory Affairs
    Innovative Medicines Canada, Canada
  • Marc F. Poitras, PhD, MBA
    Marc F. Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
  • Matthew  Ryan
    Matthew Ryan Senior Policy Analyst; Policy, Planning and International Affairs Directorate
    Health Canada, Canada
Load More

Contact us

Digital Learning Catalog

eLearning Catalog Cover
Download